Novavax Inc. (NVAX) saw its stock surge 7.61% over a 24-hour period, driven by the company's announcement of selling its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk for $200 million.
The agreement involves the transfer of a 150,000-square foot state-of-the-art recombinant protein manufacturing facility, along with the existing workforce and related infrastructure. Novavax will receive a cash payment of $190 million in 2024 and an additional $10 million in 2025.
According to Novavax, the sale aligns with the company's strategy to evolve into a leaner and more agile organization focused on partnering its pipeline assets and proven technology platform. Moreover, the company expects annual operating cost reductions of approximately $80 million from the sale.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。